Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and lymecycline. A phase II study

Supportive Care in Cancer

Volumn 21, Issue 6, 2013, Pages 1691-1695

  Grande, Roberta ^a   Narducci, Filomena ^b   Bianchetti, Sara ^c   Mansueto, Giovanni ^a   Gemma, Donatello ^b   Sperduti, Isabella ^d   Trombetta, Giorgio ^b   Angelini, Franco ^c   Gamucci, Teresa ^a  

^a ASL Frosinone   (Italy)

^b S S Trinità Hospital   (Italy)

^c Section of Pediatrics   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

EGFRI; Lung cancer; mCRC; Papulopustular rash; Skin toxicities

Indexed keywords

ANTIHISTAMINIC AGENT; CETUXIMAB; DERMATOLOGICAL AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; LYMECYCLINE; PANITUMUMAB; SKIN MOISTURIZER; STEROID; SUNSCREEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL PROTOCOL; COLORECTAL CANCER; DERMATOLOGY LIFE QUALITY INDEX; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SKIN MANIFESTATION; SKIN TOXICITY; WILD TYPE; XEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG ERUPTIONS; EMOLLIENTS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMECYCLINE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; SUNSCREENING AGENTS; TREATMENT OUTCOME;

EID: 84879151359     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1715-1     Document Type: Article

References (22)

1. Lacouture ME, Mitchell EP, Piperdi B et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. JCO Mar 10:1351-1357
2. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
3. Saltz L, Meropol NJ, Loehrer PJ et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
4. Foon KA, Yang X-D, Weiner LM et al (2004) Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58:984-990
5. Vanhoefer U, Twes M, Rojo F et al (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22:175-184
6. Seymour L, Goss G, Stewart D (2002) A translational research study of ZD1839 at a dose of 750 mg in patients with pretreated advanced or metastatic colorectal cancer: NCIC CTG IND.122. Ann Oncol 13: S5 (Abstr 264PD)
7. Oza AM, Townsley CA, Siu LL et al (2003) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22: 196 (Abstr 785)
8. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290:2149-2158
9. Hidalgo M, Siu LL, Nemunaitis J et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279
10. Van Cutsem E, Mayer R, Gold P et al (2004) Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer 2 (Suppl): 85-86 (Abstr 279)
11. Rhee J, Oishi K, Garey J et al (2005) Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin Colorectal Cancer 5(Suppl 2):S101-S106
12. Balagula Y, Wu S, Su X, Lacouture ME (2011) The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann Oncol 22(11):2366-2374. doi: 10.1093/annonc/ mdr016
13. Thatcher N, Nicolson M, Groves RW et al. (2009) Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK. Oncologist 14:840-847
14. Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21:34-36
15. Eilers RE, Gandhi M, Patel JD et al (2010) Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 102:47-53
16. Boone SL, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152-159
17. Janne PA, Gurubhagavatula S, Yeap BY et al (2004) Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib on an expanded access study. Lung Cancer 44:221-230
18. Forsythe B, Faulkner K (2004) Overview of the tolerability of gefitinib monotherapy: clinical experience in non-small cell lung cancer. Drug Saf 27:1081-1092
19. Jatoi A, Rowland K, Sloan JA et al (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847-853
20. Scope A, Agero A, Dusza S et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390-5396, 812, 2006
21. Plewig G, Kligman AM (2000) Acne and rosacea, 3rd edn. Springer, Berlin
22. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210-216